DXCM Rallies 52.5% in 3 Months. Can the Stock Keep Climbing From Here?

DexCom, Inc. DXCM shares have climbed 52.5% in the past three months, a sharp re-rating that raises the standard for further gains. The next leg depends less on momentum alone and more on whether earnings growth, margin expansion and new-market access can keep pace with higher expectations.

Recent results support the fundamental case, but the stock’s premium valuation leaves less room for disappointment. Investors now have to weigh improving execution against competition and litigation risk.

DXCM’s 52.5% Rally Outpaces Key Benchmarks

DXCM’s three-month gain easily exceeds the 18.3% rise for the Zacks sub-industry, the Zacks Medical sector’s 10.4% advance and the S&P 500’s 2.4% increase. That relative strength shows investors have rewarded DexCom more aggressively than the broader market.

The outperformance also raises the hurdle. With a larger share-price gain already captured, future upside will likely require continued earnings delivery and progress on the company’s access and product initiatives rather than simple multiple expansion.

Image Source: Zacks Investment Research

DexCom’s Q2 Beat Supports the Fundamental Case

Second-quarter 2026 revenues increased 13.1% year over year to $1.31 billion. Adjusted earnings were 70 cents per share, above the Zacks Consensus Estimate of 61 cents and up from 48 cents a year earlier.

Growth was broad-based geographically. U.S. revenues rose 11% to $933.4 million, while international revenues advanced 19% to $375 million. Coverage expansion and new-patient additions supported the U.S. business, while France and Canada were among markets benefiting from broader reimbursement.

DXCM’s Margin Gains Add Quality to the Growth Story

Adjusted gross margin reached 64.1%, up 400 basis points year over year. Adjusted operating margin improved 590 basis points to 25.1%, helped by manufacturing efficiencies, quality management and early benefits from the G7 15 Day transition.

The combination of double-digit revenue growth and wider margins makes the rally more defensible than one driven only by sales. DexCom also expects nearly 50% of its U.S. customer base to convert to G7 15 Day by year-end, while broader type 2 coverage remains a meaningful growth avenue.

DexCom’s Premium Valuation Raises the Bar

DXCM trades at 30.7X forward 12-month earnings, above 27.3X for the Zacks sub-industry, 21.2X for the Zacks Medical sector and 20.7X for the S&P 500. Earnings estimate revisions help support that premium, with 2026 and 2027 estimates up 2.7% and 1.2%, respectively, over the past 60 days.

Image Source: Zacks Investment Research

Competition remains a counterweight. Abbott ABT continues to expand its Libre continuous glucose monitoring portfolio, including new clinical evidence in basal-insulin type 2 diabetes. MiniMed Group MMED has also broadened its diabetes ecosystem through MiniMed systems and newer continuous glucose monitoring integrations. Those alternatives can intensify pricing, rebate and formulary pressure.

DXCM’s Signal Check Favors a Balanced Finish

After a 33.7% run, DexCom still has measurable support from earnings growth, margin expansion, estimate revisions and product adoption. Yet the premium multiple means execution must remain consistent, while competitive pressure and ongoing litigation create downside risk.

DXCM currently carries a Zacks Rank #3 (Hold). Likewise, Abbott carries a Zacks Rank of 3, while MiniMed has a Zacks Rank #4 (Sell).  That keeps the assessment centered on the available fundamentals: improving estimates and profitability on one side, and a richer valuation plus industry and legal risks on the other. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research